Imagine a medication that doesn’t just address performance, but reignites desire itself.
In this special episode, Dr. Jesse Haggard and Virgel discuss PT 141 (Bremelanotide), a medication that's in a class all its own.
Unlike ED meds such as Viagra or Cialis, which work on "the hardware" by enhancing blood flow (stimulating nitric oxide), PT 141 works on "the software"—your brain. It’s a melanocortin receptor agonist that stimulates the brain's pathways for sexual desire and arousal. In other words, it works on "wanting" more than just plumbing.
This episode covers:
The Origin Story: Like Viagra (originally a heart medication), PT 141 was an accidental discovery. It was developed from Melanotan II, a peptide for... tanning!
How It Works: Dr. Haggard explains the science of how it stimulates melanocortin receptors in the brain to increase arousal.
Why It's an Injection: We explore why the original intranasal spray was halted in 2007 (due to blood pressure) and why the injection is now the approved method.
For Women & Men: It was strategically FDA-approved in 2019 as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women, filling a wide-open market. It is also used very effectively off-label in men.
The Side Effects: Virgel shares his "head rush" experience, and we cover the common side effects you need to know about, including nausea (40%), flushing (20%), headache (11%), and injection site reactions.
Join us for a candid discussion on the "fifth element" of sexual medicine that's changing the game.
Disclaimer: The views and opinions expressed in this podcast are for informational purposes only and do not constitute medical advice. Please consult with a qualified healthcare professional for any medical concerns.